<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01027793</url>
  </required_header>
  <id_info>
    <org_study_id>11-CBED08-01</org_study_id>
    <nct_id>NCT01027793</nct_id>
  </id_info>
  <brief_title>Trial Comparing Treatment of Tretinoin or Superficial Dermabrasion for Stretch Marks</brief_title>
  <official_title>Randomized Clinical Trial Comparing Treatment of Tretinoin or Superficial Dermabrasion for Recent Stretch Marks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brazilan Center for Studies in Dermatology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brazilan Center for Studies in Dermatology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate head-to-head the effectiveness of tretinoin 0.5% and superficial&#xD;
      dermabrasion in subjects that have recent stretch marks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy female subjects, from 11 t0 25 years old, that have thin (1-5mm) recent(less than 6&#xD;
      months of evolution),reddish or purple line stretch marks. The striae should be symmetrical&#xD;
      and it could be located in the abdomen,breasts, upper arms, thighs (both inner and outer),&#xD;
      hips, and buttocks.&#xD;
&#xD;
      Thirty subjects will be randomly divided in two groups:&#xD;
&#xD;
      Group 1 will receive tretinoin cream that should be applied daily in areas affected by&#xD;
      stretch marks.&#xD;
&#xD;
      Group 2 will receive 16 sessions of dermabrasion that would be held in the research center.&#xD;
&#xD;
      Subjects will be evaluated by pictures, measurement of width and length of stretch marks,&#xD;
      using Mirror System(Canfield).&#xD;
&#xD;
      Biopsy to quantify alterations of epidermis and dermis of treated area, will be held&#xD;
      pre-treatment and 2 weeks after the conclusion of treatment. For biopsy will be used a punch&#xD;
      of 3mm.&#xD;
&#xD;
      The results will be evaluated two weeks after the conclusion of the interventions. An&#xD;
      independent dermatologist, blinded for intervention, will analyse pictures pre and post&#xD;
      treatment. This subjective evaluation will be performed using Global Aesthetic Improvement&#xD;
      Scale.&#xD;
&#xD;
      Safety and adverse events will be assessed each visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Width of Stretch Marks</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>Striae width was measured with Mirror Medical Imaging Software (Canfield Scientific, Inc., Parsippany, NJ)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of Stretch Marks</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>Striae length was measured with Mirror Medical Imaging Software (Canfield Scientific, Inc., Parsippany, NJ)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global Aesthetic Improvement Scale</measure>
    <time_frame>16 weeks</time_frame>
    <description>Very much improved: Optimal cosmetic result for the implant in this patient&#xD;
Much improved: Marked improvement in appearance from the initial condition but not completely optimal for this patient; touch-up would slightly improve the result 3 - Improved: Obvious improvement in appearance from the initial condition, but touch-up or retreatment is indicated 4 - No change: Appearance essentially the same as the original condition 5 - Worse: Appearance worse than the original condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>16 weeks</time_frame>
    <description>Patient satisfaction measured with Lickert scale (Very satisfied, Satisfied, Neither satisfied nor unsatisfied, unsatisfied, very unsatisfied)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Stretch Marks</condition>
  <condition>Striae</condition>
  <condition>Treatment</condition>
  <arm_group>
    <arm_group_label>Tretinoin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Superficial Dermabrasion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 will receive 16 sessions of dermabrasion that would be held in the research center.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tretinoin cream 0.005%</intervention_name>
    <description>Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.</description>
    <arm_group_label>Tretinoin</arm_group_label>
    <other_name>(Vitanol A, Stiefel)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Superficial Dermabrasion</intervention_name>
    <description>Group 2 will receive 16 sessions of dermabrasion that would be held in the research center</description>
    <arm_group_label>Superficial Dermabrasion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female subjects, aged between 11 and 25 years&#xD;
&#xD;
          -  Female subjects of childbearing age that present a negative urine pregnancy test and&#xD;
             are using an effective contraceptive method for at least 3 months prior the study&#xD;
&#xD;
          -  Subjects that have thin (1-5mm) recent(less than 6 months of evolution),reddish or&#xD;
             purple line stretch marks. The striae should be symmetrical and it could be located in&#xD;
             the abdomen,breasts, upper arms, thighs (both inner and outer), hips, and buttocks&#xD;
&#xD;
          -  Subjects agreeing to take part of the study, after being fully informed of the purpose&#xD;
             and the nature of the investigation and after having signed the informed consent form&#xD;
&#xD;
          -  Subjects with sufficient schooling and awareness to enable them to cooperate to the&#xD;
             degree required by this protocol&#xD;
&#xD;
          -  Subjects who had never received treatment for striae in the studied area&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects whose medical history and physical examination present clinical pathology, as&#xD;
             marfan Syndrome, cushing, systemic autoimmune or neurological diseases&#xD;
&#xD;
          -  Pregnant or women in breastfeeding, or women planning to become pregnant&#xD;
&#xD;
          -  Previous treatment for striae in the local area of the study.&#xD;
&#xD;
          -  Subjects that are in use of tretinoin or glycolic acid in the local area of the study.&#xD;
&#xD;
          -  Presence of white striae in the local area of the study&#xD;
&#xD;
          -  History of Connective Tissue Disease&#xD;
&#xD;
          -  History of keloid development or skin healing problems&#xD;
&#xD;
          -  Subjects that are taking medications associated with striae development, as systemic&#xD;
             corticosteroids, indinavir, hormonal replacement therapy&#xD;
&#xD;
          -  Hypersensibility to retinoic acid&#xD;
&#xD;
          -  Subjects who intend to get tan in the area of the study, through exposure of sun or&#xD;
             tanning machines during the study&#xD;
&#xD;
          -  Subjects that have a variation in their weight of more than 2 kg in a period of four&#xD;
             months prior the study&#xD;
&#xD;
          -  Predisposition for chronic inflammatory process&#xD;
&#xD;
          -  Subjects with chronic diseases as diabetes, cardiopathy, neoplasm, HIV and autoimmune&#xD;
             diseases (vitiligo, lupus)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doris M Hexsel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brazilian Center For Studies in Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brazilian Center for Studies in Dermatology</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90570 040</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 8, 2009</study_first_submitted>
  <study_first_submitted_qc>December 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2009</study_first_posted>
  <results_first_submitted>December 7, 2020</results_first_submitted>
  <results_first_submitted_qc>January 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2021</results_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brazilan Center for Studies in Dermatology</investigator_affiliation>
    <investigator_full_name>Doris Hexsel</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Stretch marks</keyword>
  <keyword>Striae</keyword>
  <keyword>Tretinoin</keyword>
  <keyword>Superficial dermabrasion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Striae Distensae</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tretinoin</title>
          <description>Group 1 will receive tretinoin cream 0.05% (Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.&#xD;
Tretinoin cream 0.005%: Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Superficial Dermabrasion</title>
          <description>Group 2 will receive 16 sessions of dermabrasion that would be held in the research center.&#xD;
Superficial Dermabrasion: Group 2 will receive 16 sessions of dermabrasion that would be held in the research center</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Per protocol assessment</population>
      <group_list>
        <group group_id="B1">
          <title>Tretinoin</title>
          <description>Group 1 will receive tretinoin cream 0.05% (Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.&#xD;
Tretinoin cream 0.005%: Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Superficial Dermabrasion</title>
          <description>Group 2 will receive 16 sessions of dermabrasion that would be held in the research center.&#xD;
Superficial Dermabrasion: Group 2 will receive 16 sessions of dermabrasion that would be held in the research center</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.7" spread="4.3"/>
                    <measurement group_id="B2" value="17.0" spread="3.2"/>
                    <measurement group_id="B3" value="16.9" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fitzpatrick skin phototype</title>
          <description>Phototype I - Pale white skin, blue/green eyes, blond/red hair; Always burns, does not tan Phototype II - Fair skin, blue eyes; Burns easily, tans poorly Phototype III - Darker white skin; Tans after initial burn Phototype IV - Light brown skin; Burns minimally, tans easily Phototype V - Brown skin; Rarely burns, tans darkly easily Phototype VI - Dark brown or black skin; Never burns, always tans darkly</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Fitzpatrick skin phototype I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fitzpatrick skin phototype II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fitzpatrick skin phototype III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fitzpatrick skin phototype IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fitzpatrick skin phototype V</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fitzpatrick skin phototype VI</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.7" spread="4.4"/>
                    <measurement group_id="B2" value="24.8" spread="3.3"/>
                    <measurement group_id="B3" value="24.3" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Width of Stretch Marks</title>
        <description>Striae width was measured with Mirror Medical Imaging Software (Canfield Scientific, Inc., Parsippany, NJ)</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <population>Per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Tretinoin</title>
            <description>Group 1 will receive tretinoin cream 0.05% (Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.&#xD;
Tretinoin cream 0.005%: Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Superficial Dermabrasion</title>
            <description>Group 2 will receive 16 sessions of dermabrasion that would be held in the research center.&#xD;
Superficial Dermabrasion: Group 2 will receive 16 sessions of dermabrasion that would be held in the research center</description>
          </group>
        </group_list>
        <measure>
          <title>Width of Stretch Marks</title>
          <description>Striae width was measured with Mirror Medical Imaging Software (Canfield Scientific, Inc., Parsippany, NJ)</description>
          <population>Per protocol.</population>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.199" spread="0.129"/>
                    <measurement group_id="O2" value="0.146" spread="0.052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.088" spread="0.073"/>
                    <measurement group_id="O2" value="0.077" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Length of Stretch Marks</title>
        <description>Striae length was measured with Mirror Medical Imaging Software (Canfield Scientific, Inc., Parsippany, NJ)</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <population>Per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Tretinoin</title>
            <description>Group 1 will receive tretinoin cream 0.05% (Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.&#xD;
Tretinoin cream 0.005%: Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Superficial Dermabrasion</title>
            <description>Group 2 will receive 16 sessions of dermabrasion that would be held in the research center.&#xD;
Superficial Dermabrasion: Group 2 will receive 16 sessions of dermabrasion that would be held in the research center</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stretch Marks</title>
          <description>Striae length was measured with Mirror Medical Imaging Software (Canfield Scientific, Inc., Parsippany, NJ)</description>
          <population>Per protocol.</population>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.371" spread="0.631"/>
                    <measurement group_id="O2" value="1.518" spread="0.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.894" spread="0.457"/>
                    <measurement group_id="O2" value="1.111" spread="0.673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Aesthetic Improvement Scale</title>
        <description>Very much improved: Optimal cosmetic result for the implant in this patient&#xD;
Much improved: Marked improvement in appearance from the initial condition but not completely optimal for this patient; touch-up would slightly improve the result 3 - Improved: Obvious improvement in appearance from the initial condition, but touch-up or retreatment is indicated 4 - No change: Appearance essentially the same as the original condition 5 - Worse: Appearance worse than the original condition</description>
        <time_frame>16 weeks</time_frame>
        <population>Per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Tretinoin</title>
            <description>Group 1 will receive tretinoin cream 0.05% (Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.&#xD;
Tretinoin cream 0.005%: Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Superficial Dermabrasion</title>
            <description>Group 2 will receive 16 sessions of dermabrasion that would be held in the research center.&#xD;
Superficial Dermabrasion: Group 2 will receive 16 sessions of dermabrasion that would be held in the research center</description>
          </group>
        </group_list>
        <measure>
          <title>Global Aesthetic Improvement Scale</title>
          <description>Very much improved: Optimal cosmetic result for the implant in this patient&#xD;
Much improved: Marked improvement in appearance from the initial condition but not completely optimal for this patient; touch-up would slightly improve the result 3 - Improved: Obvious improvement in appearance from the initial condition, but touch-up or retreatment is indicated 4 - No change: Appearance essentially the same as the original condition 5 - Worse: Appearance worse than the original condition</description>
          <population>Per protocol.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction</title>
        <description>Patient satisfaction measured with Lickert scale (Very satisfied, Satisfied, Neither satisfied nor unsatisfied, unsatisfied, very unsatisfied)</description>
        <time_frame>16 weeks</time_frame>
        <population>Per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Tretinoin</title>
            <description>Group 1 will receive tretinoin cream 0.05% (Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.&#xD;
Tretinoin cream 0.005%: Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Superficial Dermabrasion</title>
            <description>Group 2 will receive 16 sessions of dermabrasion that would be held in the research center.&#xD;
Superficial Dermabrasion: Group 2 will receive 16 sessions of dermabrasion that would be held in the research center</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction</title>
          <description>Patient satisfaction measured with Lickert scale (Very satisfied, Satisfied, Neither satisfied nor unsatisfied, unsatisfied, very unsatisfied)</description>
          <population>Per protocol.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither satisfied nor unsatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tretinoin</title>
          <description>Group 1 will receive tretinoin cream 0.05% (Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.&#xD;
Tretinoin cream 0.005%: Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Superficial Dermabrasion</title>
          <description>Group 2 will receive 16 sessions of dermabrasion that would be held in the research center.&#xD;
Superficial Dermabrasion: Group 2 will receive 16 sessions of dermabrasion that would be held in the research center</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <description>Itching on the treated area.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <description>Erythema on the treated area.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Scaling</sub_title>
                <description>Scaling on the treated area</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Stinging</sub_title>
                <description>Stinging on the treated area</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Doris Hexsel</name_or_title>
      <organization>Brazilian Center for Studies in Dermatology</organization>
      <phone>+55 51 30262633</phone>
      <email>cientifico@cbed.org.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

